Press release
Primary Biliary Cholangitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
Explore our latest breakthroughs in Primary Biliary Cholangitis Research. Learn more about our innovative pipeline today! @ Primary Biliary Cholangitis Pipeline Outlook [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Primary Biliary Cholangitis Pipeline Report
* June 2024:- Zydus Therapeutics Inc .- A Multicenter, Open-Label, Extension Clinical Trial to Evaluate Safety and Efficacy of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis (PBC). A Multicenter, Open-Label, Extension Clinical trial to evaluate Safety and Efficacy of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis (PBC).
* June 2024:- CymaBay Therapeutics Inc.- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis. To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
* June 2024:- COUR Pharmaceuticals Development Company Inc.- A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA. This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-104. The study consists of a 120 day primary study followed by a 20 month long-term safety and durability of response follow-up period.
* June 2024:- Calliditas Therapeutics Suisse SA - The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).
* June 2024:- Ipsen - A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts.
* June 2024:- Mirum Pharmaceuticals, Inc.- A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis. The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
* June 2024:- GlaxoSmithKline - A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC). This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
* DelveInsight's Primary Biliary Cholangitis pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Primary Biliary Cholangitis treatment.
* The leading Primary Biliary Cholangitis Companies such as Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis, CymaBay Therapeutic s, and others.
* Promising Primary Biliary Cholangitis Therapies such as Saroglitazar Magnesium 1 mg, Seladelpar 10 mg, Obeticholic Acid Tablets , and others.
Stay informed about the cutting-edge advancements in Primary Biliary Cholangitis Treatments. Download for updates and be a part of the revolution in cancer care @ Primary Biliary Cholangitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Primary Biliary Cholangitis Emerging Drugs Profile
* Elafibranor: Genfit
Elafibranor is a dual agonist of the PPAR and PPAR. Meaning the drug candidate acts simultaneously on the two nuclear receptors, which both play an important role in numerous processes involved in the development of NASH and its co-morbidities. It has shown highly significant results in its Phase 2 Study in patients with primary biliary cholangitis (PBC), while maintaining a favorable tolerability profile and lack of demonstrated safety concerns, paving the way for advancement into phase 3 clinical trial in 2020. It has recently been granted Breakthrough Therapy Designation by the FDA for the treatment of Primary Biliary Cholangitis (PBC) in adults with inadequate response to ursodeoxycholic acid (UDCA), as well as Orphan Drug Designation by the FDA and the EMA (European Medicines Agency).
* ASC42: Gannex Pharma
ASC42 is a novel non-steroidal, selective, potent FXR agonist. It has shown positive results in its Phase I Study in patients with primary biliary cholangitis with no pruritus observed and LDL-C remained within normal range at the human therapeutic dose of 15 mg. The drug is in Phase II stage of its clinical studies for Primary Biliary Cholangitis.
* OP-724: Ohara Pharmaceutical
OP-724 is a synthetic small molecule which is an inhibitor of cyclic AMP response element-binding protein (CREB)-binding protein (CBP)/-catenin. Ohara Pharmaceutical obtained development rights for OP-724 from PRISM BioLab in 2018 . The drug is in Phase I stage of its clinical studies for Primary Biliary Cholangitis.
Learn more about Primary Biliary Cholangitis Drugs opportunities in our groundbreaking Primary Biliary Cholangitis Research and development projects @ Primary Biliary Cholangitis Unmet Needs [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Primary Biliary Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Primary Biliary Cholangitis Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Discover the latest advancements in Primary Biliary Cholangitis Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Primary Biliary Cholangitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Primary Biliary Cholangitis Pipeline Report
* Coverage- Global
* Primary Biliary Cholangitis Companies- Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis, CymaBay Therapeutics, and others.
* Primary Biliary Cholangitis Therapies- Saroglitazar Magnesium 1 mg, Seladelpar 10 mg, Obeticholic Acid Tablets, and others.
* Primary Biliary Cholangitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Primary Biliary Cholangitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Primary Biliary Cholangitis Pipeline on our website @ Primary Biliary Cholangitis Drugs and Companies [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Primary Biliary Cholangitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Primary Biliary Cholangitis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Elafibranor: Genfit
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ASC42: Gannex Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* OP-724: Ohara Pharmaceutical
* Drug profiles in the detailed report.....
* Inactive Products
* Primary Biliary Cholangitis Key Companies
* Primary Biliary Cholangitis Key Products
* Primary Biliary Cholangitis- Unmet Needs
* Primary Biliary Cholangitis- Market Drivers and Barriers
* Primary Biliary Cholangitis- Future Perspectives and Conclusion
* Primary Biliary Cholangitis Analyst Views
* Primary Biliary Cholangitis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-biliary-cholangitis-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Biliary Cholangitis Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here
News-ID: 3549210 • Views: …
More Releases from ABNewswire
Drug Discovery Services Market: Global Growth Outlook, Key Drivers, and Competit …
Browse 577 market data Tables and 64 Figures spread through 450 Pages and in-depth TOC on "Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030
The Drug Discovery Services Market is undergoing significant expansion as pharmaceutical and biopharmaceutical companies increase their investments in research and development. Valued at…
Enterprise Content Management Market Recent Technological Developments, Growth, …
Enterprise Content Management Market by Offering (Solutions (Document Management, Case Management, Record Management, Imaging & Capturing)), Business Function (Sales & Marketing, Accounting & Legal, Procurement & SCM) - Global Forecast to 2029.
The Enterprise Content Management Market [https://www.marketsandmarkets.com/Market-Reports/enterprise-content-management-market-226977096.html?utm_campaign=enterprisecontentmanagementmarket&utm_source=abnewswire.com&utm_medium=referral] is expected to increase at a compound annual growth rate (CAGR) of 10.5% from USD 47.6 billion in 2024 to USD 78.4 billion by 2029. The quickly developing enterprise content management market has…
Satellite Solar Cell Materials Market Outlook (2025-2030): Latest Trends, Growth …
The Satellite Solar Cell Materials Market is growing steadily, driven by increasing satellite launches, rising demand for high-efficiency power systems, and advancements in space-grade photovoltaic technologies. Key players such as AZUR SPACE, Spectrolab, SolAero Technologies, Thales Alenia Space, and Hanwha Q Cells are focusing on durable, lightweight, and high-efficiency materials to enhance satellite performance and mission lifespan.
The satellite solar cell materials market is projected to reach USD 96 million by…
Medical Membranes Market Industry Analysis by Size, Share, Growth, Sourcing Stra …
The Medical Membranes Market is witnessing strong growth driven by rising demand for advanced filtration, drug delivery, and diagnostic applications. Key players such as Merck Millipore, Pall Corporation, GE Healthcare, Asahi Kasei, and Sartorius are focusing on high-performance membranes, improved biocompatibility, and innovative purification technologies to support the expanding healthcare and biopharmaceutical sectors.
The medical membranes market is projected to reach USD 6.66 billion by 2030 from USD 4.31 billion in…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
